The Proliferative Diabetic Retinopathy (PDR) drugs in development market research report provides comprehensive information on the therapeutics under development for Proliferative Diabetic Retinopathy (PDR), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Proliferative Diabetic Retinopathy (PDR). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Proliferative Diabetic Retinopathy (PDR) and features dormant and discontinued products.

GlobalData tracks eight drugs in development for Proliferative Diabetic Retinopathy (PDR) by eight companies/universities/institutes. The top development phase for Proliferative Diabetic Retinopathy (PDR) is phase ii with five drugs in that stage. The Proliferative Diabetic Retinopathy (PDR) pipeline has seven drugs in development by companies and one by universities/ institutes. Some of the companies in the Proliferative Diabetic Retinopathy (PDR) pipeline products market are: Boehringer Ingelheim International, Kubota Vision and Ribomic.

The key targets in the Proliferative Diabetic Retinopathy (PDR) pipeline products market include Periostin (Osteoblast Specific Factor 2 or POSTN), Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1), and Retinoid Isomerohydrolase (All Trans Retinyl Palmitate Hydrolase or Retinal Pigment Epithelium Specific 65 kDa Protein or Retinol Isomerase or RPE65 or EC 3.1.1.64).

The key mechanisms of action in the Proliferative Diabetic Retinopathy (PDR) pipeline product include Vascular Endothelial Growth Factor A (Vascular Permeability Factor or VEGFA) Inhibitor with one drug in Phase III. The Proliferative Diabetic Retinopathy (PDR) pipeline products include four routes of administration with the top ROA being Oral and three key molecule types in the Proliferative Diabetic Retinopathy (PDR) pipeline products market including Small Molecule, and Aptamer.

Proliferative Diabetic Retinopathy (PDR) overview

Proliferative diabetic retinopathy (PDR) is the most severe type of diabetic retinopathy. PDR occurs where fragile new blood vessels form on the surface of the retina over time. These abnormal vessels can bleed or develop scar tissue, causing severe loss of sight. Predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy, and tobacco use. Symptoms include spots or dark strings floating in vision, vision loss, fluctuating vision, blurred vision, and difficulty with color perception.

For a complete picture of Proliferative Diabetic Retinopathy (PDR)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.